Tesamorelin – 20mg

Tesamorelin (chemically engineered as a stabilized Growth Hormone-Releasing Hormone analog) is a synthetic 44-amino-acid peptide that represents the absolute pinnacle of targeted endocrine secretion research. It mirrors the exact structural activity of endogenous GHRH but features an N-terminal modification—specifically a trans-3-hexenoic acid group attached to the tyrosine residue at position 1. This strategic alteration grants Tesamorelin extreme resistance to rapid cleavage by the dipeptidyl peptidase-4 (DPP-4) enzyme, providing it with a vastly superior half-life and potency profile compared to native GHRH. In laboratory models, it is the primary compound used to study the selective elimination of deep visceral adipose tissue and the optimization of natural, pulsatile growth hormone signaling cascades. [1, 2, 3, 4]

Key Features & Characteristics

• Mechanism of Action: Binds directly and with high affinity to GHRH receptors on pituitary somatotropes, instructing the anterior pituitary to synthesize and release endogenous growth hormone. [1, 2]
• Preserved Somatotropic Pulsatility: Unlike direct exogenous growth hormone administration, Tesamorelin works completely upstream, maintaining native negative-feedback loops and physiological pulsatile release rhythms. [1, 2]
• Adipocyte Compartment Selectivity: Displays a distinct, highly documented capability to drive lipolysis inside deep visceral fat depots (the fat wrapped around internal organs) while largely sparing subcutaneous fat layers. [1, 2]
• Physical Form: Produced via high-fidelity automated solid-phase synthesis and supplied as an ultra-pure, white lyophilized powder requiring precise fluid configuration. [1]

Primary Research Applications

• Visceral Adiposity & Lipodystrophy: Widely utilized in metabolic disease and lipodystrophy models to analyze changes in waist circumference, absolute lipid-to-water ratios, and deep visceral adipose tissue (VAT) reduction.
• Anabolic Muscle & Lean Mass Retention: Investigated in physical wasting and muscle preservation protocols to track how downstream Insulin-like Growth Factor 1 (IGF-1) elevation stimulates structural protein synthesis and maintains nitrogen balances.
• Hepatic Steatosis & Cardiovascular Risk: Studied in preclinical metabolic syndrome profiles to monitor absolute reductions in liver fat accumulation (ectopic fat) and track corresponding enhancements in circulating lipid fractions.
• Neurocognitive Longevity: Evaluated in aging and neurodegenerative models due to early research indicating that optimizing the GHRH-GH-IGF-1 axis may support mild cognitive clarity and combat brain health decline. [, 2, 3, 4, 5, 6, 7, 8]

For Research Use Only. Not for human consumption, therapeutic, or diagnostic use.